Fresenius Group Overview

Investors

Fresenius Investment Highlights

  • Diversified revenue and earnings base with four strong business segments

  • Leading positions in non-cyclical markets with predictable growth

  • Industry-leading organic growth in all business segments

  • Strong earnings performance and cash flow generation

  • Attractive shareholder returns

  • Prudent financial management

"The first half of 2018 was a very good one for Fresenius. After our successful start, we have delivered a strong second quarter with continued healthy growth in sales and earnings. All four business segments contributed to this, and all four business segments display outstanding prospects for the future. For Fresenius Kabi, we are even a bit more optimistic than before. We are therefore fully on track to achieve our ambitious growth targets as we steer toward another excellent year for Fresenius."
(Stephan Sturm, Chairman of the Management Board)

News

  • Fresenius confirms and narrows Group guidance for FY/18 and publishes preliminary results for Q3/18
    October 16, 2018Fresenius
    Brief News
    Fresenius Kabi opens compounding center in Canada

    Fresenius Kabi has opened a new state-of-the-art compounding center in Canada. It involves an investment of 11 million Canadian dollars (more than €7 million), and the new site expands the company’s presence in Mississauga, Ontario. Fresenius Kabi is responding to increasing demand for large batches of compounded medications for patients in Canadian hospitals, and the 35,000-square-foot (3,300-square-meter) compounding center has the capacity to expand. The new facility is expected to employ 70 people by 2022.

    October 16, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi biosimilar candidate meets primary endpoints in the two pivotal clinical studies

    Fresenius Kabi has reached a milestone on the road to approval for another biosimilar. MSB11455, a biosimilar candidate for Neulasta® (pegfilgrastim), has met its primary endpoints in the two pivotal clinical studies. For more information please see the website of Fresenius Kabi.

    October 09, 2018Fresenius Kabi
    Brief News
    2019 DRG inflator for German hospitals set at 2.65%

    The price increase for hospital services in Germany has been set at 2.65% for 2019. This is in line with the level of past years.

    September 17, 2018Fresenius Helios
  • Brief News
    Fresenius Helios opens new hospital in Cordoba

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, is opening a new hospital in Cordoba today. The company now has six hospitals in Andalusia, Spain’s most southernly autonomous community. The six-floor, approximately 25,000-square-meter (269,000-square-foot) facility includes 100 large private patient rooms, a 24-hour emergency department, seven operating rooms and a surgical outpatient clinic. Quirónsalud has invested €50 million in the new hospital.    

    September 17, 2018Fresenius Helios
    Brief News
    Fresenius Helios opens emergency unit in eastern Germany

    Fresenius Helios has opened a new emergency unit at Helios Hospital Leisnig, in the eastern German state of Saxony. It contains four modern examination rooms and a specially equipped reanimation room, which will enable the hospital to provide even better care for its emergency patients, who now number some 10,000 annually. Architecturally optimized for medical processes and procedures, the new emergency unit was built in only 12 months. It required an investment by Fresenius Helios of about €1 million.

    August 28, 2018Fresenius Helios
  • Fresenius posts strong second quarter and confirms Group guidance – Continued net income growth – EBIT outlook raised for Fresenius Kabi
    July 31, 2018Fresenius
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Atropine Sulfate Injection further expands the company's anesthesia and analgesia portfolio.

    July 19, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Glycopyrrolate Injection is the newest addition to the company’s anesthesia and analgesia portfolio. 

    July 18, 2018Fresenius Kabi
    Brief News
    Fresenius Helios to partner with first online medical studies program

    Fresenius Helios will take responsibility for practical instruction as part of the first worldwide digitalized medical studies program. The new course of study meets European certification standards and will start in the winter semester 2018/2019 at the EDU College of Medicine, Malta. Theoretical components of a bachelor’s and follow-on master’s program will be available solely via an online platform. Students will be networked into learning communities taught by faculty. About one-third of the course is practical instruction that will take place in hospitals operated by Fresenius Helios in Germany. The program initially will be limited to 75 students. The long-term goal is up to 3,000 students.

    July 03, 2018Fresenius Helios
  • Brief News
    Fresenius Kabi expanding operations at UK site

    Fresenius Kabi is expanding its production and warehouse capacity in Runcorn, England, to meet increasing demand in United Kingdom’s homecare market and from UK and Ireland hospitals. The expansion’s first stage will be a new distribution and operations center, scheduled to open in early 2019. A second services unit for producing aseptically compounded parenteral nutrition products will be completed by 2020. Fresenius Kabi will invest over €9 million in the expansion.

    June 27, 2018Fresenius Kabi
    Fresenius Helios Capital Markets Day: Cross-border knowledge exchange creates basis for further growth
    June 08, 2018Fresenius Helios
  • Fresenius transfers inpatient rehabilitation business from Fresenius Helios to Fresenius Vamed
    June 06, 2018Fresenius Helios
    Fresenius makes excellent start to 2018, with strong sales and net income growth in constant currency
    May 03, 2018Fresenius
  • Brief News
    Fresenius Helios hospital gets highest rating in Spain

    Jiménez Díaz Foundation University Hospital in Madrid has again been awarded the EFQM Recognized for Excellence award with the maximum five stars, this time also receiving the highest rating of any hospital in Spain. The 667-bed facility earned more than 650 points on the rating scale used by the European Foundation for Quality Management during a comprehensive management and process evaluation earlier this year. In the award presentation, the EFQM cited Jiménez Díaz Foundation University Hospital’s intensive focus on patient care, as well as its continuous improvements in treatments and the use of medical technology. This leading teaching hospital is part of the Quirónsalud group, the Spanish unit of Fresenius Helios.

    April 27, 2018Fresenius Helios
    Fresenius terminates merger agreement with Akorn
    April 22, 2018Fresenius Kabi
  • Brief News
    Fresenius Kabi launches IV Cancer Drug in the U.S.

    Melphalan Hydrochloride for Injection is the newest addition to the company’s oncology portfolio.

    April 16, 2018Fresenius Kabi
    Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Palonosetron Hydrochloride Injection is the newest addition to the company’s expanding portfolio of IV drugs. It is an antiemetic that can be used for chemotherapy-induced nausea and vomiting.

    April 11, 2018Fresenius Kabi
  • Brief News
    Fresenius Helios opens new ICU in Tenerife

    Quirónsalud Tenerife Hospital has opened a new intensive care unit, equipped with the latest medical equipment for treating as many as six critically ill patients at a time. Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, invested more than €1 million in the 400-square-meter (4,300-square-foot) ICU.

    April 06, 2018Fresenius Helios
    Fresenius reports 14th consecutive record year, aims at strong growth in 2018 and confirms mid-term growth targets
    February 26, 2018Fresenius
  • Brief News
    Fresenius Helios expands two hospitals in Germany

    Fresenius Helios recently opened a 130-bed building at the company’s hospital in Dachau, a city near Munich. The new structure is part of a €55 million renovation and expansion program that will include a modernization of the existing hospital building over the next two years. Meanwhile, in the northern German city of Nienburg/Weser, work has started on a building that will almost double the size of the emergency department at Fresenius Hospital Mittelweser. About €2.3 million is being invested in this project, which is scheduled for completion in the autumn.

    February 20, 2018Fresenius Helios
    Brief News
    Fresenius Helios presents inaugural science prize

    Fresenius Helios has presented the new Helios Science Prize for outstanding research by employees that contributes to improved treatment quality. The three winners all work at hospitals in Germany and were honored for their work in different areas of medicine. The prize, which comes with a cash award, went to Dr. Jitka Veldema of Helios Hospital Kipfenberg (for her work on stroke rehabilitation), Prof. Dr. Alexander Kreuter of Helios St. Elisabeth Hospital in Oberhausen (cancer diagnosis in HIV patients), and Dr. Patrick Weil of Helios University Hospital in Wuppertal (testicular cancer therapy).

    February 02, 2018Fresenius Helios
  • Brief News
    Fresenius Kabi launches IV Drug in the U.S.

    Remifentanil is the newest addition to the company’s extensive portfolio of anesthesia and analgesia products. Remifentanil is a controlled substance sold only to licensed health care professionals for patient care and is distributed under strict controls in compliance with FDA and DEA regulations.

    January 29, 2018Fresenius Kabi
    Brief News
    S&P lifts Fresenius' rating outlook to positive

    Standard & Poor’s has revised Fresenius’ corporate credit outlook to positive from stable in late December 2017. The corporate credit rating was affirmed. Hence, Fresenius is now rated BBB- with positive outlook by Standard & Poor’s. Fresenius is rated investment grade by all of the three leading rating agencies Standard & Poor’s, Moody's and Fitch.

    January 19, 2018Fresenius
  • Brief News
    Fresenius Vamed wins awards for spa and wellness facilities

    VAMED Vitality World has been named the “World’s Best Thermal Spa & Medical Wellness Operator 2017” at the World Spa Awards. Three VAMED Vitality World facilities – St. Martins Thermal Spa & Lodge and Thermal Spa Laa Hotel & Spa, both in Austria, and Aquaworld Resort Budapest in the Hungarian capital – also won in their individual categories. VAMED Vitality World, part of Fresenius Vamed, operates a total of nine spa and health resorts in Austria and Hungary.

    January 16, 2018Fresenius Vamed
    Brief News
    Fresenius Kabi launches IV Cancer Drug in the U.S.

    Bortezomib for intravenous use is the first and only available alternative to Bortezomib for Injection and is the newest addition to the company’s expanding oncology portfolio. 

    January 04, 2018Fresenius Kabi
  • Fresenius expects meaningful positive effects from US tax reform
    December 22, 2017Fresenius
    Brief News
    Fresenius Helios builds new hospital in Spain

    Quirónsalud, the Spanish hospital group that is part of Fresenius Helios, will build a hospital in the city of Alcalá de Henares, just outside of Madrid. The approximately 11,000-square-meter (118,000-square-foot) facility will include 106 beds, four operating rooms and two delivery rooms. Quirónsalud will invest about €27 million in the new hospital. It is scheduled to open in 2019.

    December 20, 2017Fresenius Helios
  • Brief News
    Fresenius submits first biosimilar Marketing Authorization Application

    Fresenius Kabi has submitted a Marketing Authorization Application to the European Medicines Agency for its adalimumab biosimilar candidate of Humira®. The application is the first biosimilar regulatory filing for Fresenius Kabi. Adalimumab is approved in the EU for use in the treatment of chronic inflammatory autoimmune conditions, including different types of arthritis or Crohn's disease.

    December 18, 2017Fresenius Kabi
    Brief News
    Fresenius Kabi opens production facility in Indonesia

    Fresenius Kabi is expanding its activities in Indonesia. PT ETHICA Industri Farmasi, a joint venture of Fresenius Kabi and the Indonesian pharmaceuticals company SOHO Global Health, opened a new plant in Cikarang, just outside the country’s capital and biggest city Jakarta. The plant’s approximately 230 employees will produce a wide range of injectable drugs needed in therapeutic areas including gynecology, anesthesia and intensive care. The products are planned for use by Indonesian patients and for export to other Southeast Asian countries. Fresenius Kabi employs a total of about 530 people in Indonesia.

    November 24, 2017Fresenius Kabi
Disclaimer All News

Library

All Financial Reports

Information & Order Service

Stay informed about the latest news and developments at our Group by subscribing to our Investor News and/or to the Fresenius Brief News. These services are free of charge and may be cancelled at any time.

Please enter your first name.
Please enter your last name.
Please enter your company.
Please enter your department.
Please enter your function.
Please enter your street.
Please enter your postal code and city.
Please enter your e-mail address.

Please send me via email


Do you have other questions or need any more information?
Please send us a message:

To unsubscribe to these services, please send a brief e-mail to ir-fre@fresenius.com or call +49 (0) 6172 608-2470. 

Contact us

Fresenius SE & Co. KGaA
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany
T +49 (0) 6172 608-0
pr-fre@fresenius.com


Contact
Visit us

Fresenius SE & Co. KGaA

Fresenius uses cookies on this website to enhance the user experience and provide the best possible service. By continuing to browse the website, you consent to our use of cookies.

Learn more
OK